health
Ensitrelvir PEP Unlikely to Be Cost-Effective in Japan, Model Finds
A medRxiv preprint estimates that ensitrelvir post-exposure prophylaxis for high-risk household contacts in Japan would cost JPY 16.82 million per QALY gained. The model found this was unlikely to meet Japan’s JPY 5 million-per-QALY cost-effectiveness threshold.